Our group has been at the forefront of ADHD research for over a decade. We have led several prominent studies showing that structural changes in our genetic material called copy number variations (CNVs) are associated with ADHD. Specifically, we identified a set of nearly 300 genes in a network of genes called the metabotropic glutamatergic network (mGluR) that are found at a significantly higher frequency in children with ADHD. CNVs in these genes were detected in 11.3% of ADHD cases versus 1.2% of controls - a 10-fold enrichment.

We are conducting clinical trials using a small synthetic molecule and metabotropic glutamate receptor activator known as NFC-1 (fasoracetam monohydrate). These will allow us to determine the safety and efficacy of NFC-1 in alleviating ADHD symptoms in patients with mutations in glutamatergic network genes.

Recent findings from our group suggest that treatment with NFC-1 is safe and can be successful in treating symptoms of ADHD.